10-Q quarterly report · filed Nov 6, 2026

Moderna (MRNA) Q3 2026 10-Q Quarterly Report

Short answer

Moderna (MRNA) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.3B (up 29.2% year over year) with net income of $162M.

Q3 2026 key financials · XBRL

Revenue
$1.3B
+29.2% YoY · +805.5% QoQ
Net income
$162M
+181.0% YoY · +120.7% QoQ
Operating margin
9.9%
EPS (diluted)
$0.43
+184.3% YoY · +121.9% QoQ

Source: XBRL data from the Moderna (MRNA) Q3 2026 10-Q on SEC EDGAR. USD.

Moderna Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Risk Factors

  • Newly added convertible-notes risk, triggered by issuance of 0.00% Convertible Senior Notes due 2032
  • Liquidity risk: insufficient cash or financing for maturity repayment, conversion settlements, or fundamental-change repurchases
  • Default risk: credit agreement restrictions could prevent cash payments required under the notes’ indenture
  • Dilution risk: share-based conversion may dilute stockholders and pressure common-stock prices
  • Counterparty risk: uncapped exposure to financial institutions under unsecured capped call transactions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Moderna quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.